Albumin And Creatinine Tests Global Market Report 2025

The albumin and creatinine tests market size has grown exponentially in recent years. It will grow from $2.95 billion in 2024 to $3.61 billion in 2025 at a compound annual growth rate (CAGR) of 22.6%. The growth in the historic period can be attributed to the rising prevalence of chronic kidney disease (CKD) and diabetes, increased awareness of early diagnostic tools for renal health, greater adoption of point-of-care testing devices, expanding healthcare infrastructure in emerging markets, and advancements in diagnostic testing technologies.

The albumin and creatinine tests market size is expected to see exponential growth in the next few years. It will grow to $8.05 billion in 2029 at a compound annual growth rate (CAGR) of 22.2%. The growth in the forecast period can be attributed to the rising demand for home-based and remote diagnostic solutions, increased integration of AI in diagnostic tools for precision testing, a growing emphasis on preventive healthcare and early disease detection, the expansion of personalized medicine approaches, and government initiatives supporting kidney health awareness programs. Key trends include the development of automated and portable diagnostic systems, greater adoption of telemedicine-enabled diagnostic solutions, advancements in biomarkers for more accurate renal function testing, the growth of lab-on-chip technologies for point-of-care applications, and increasing collaborations between diagnostic companies and research institutions.

The increasing prevalence of chronic kidney diseases is expected to drive the growth of the albumin and creatinine tests market. Chronic kidney disease (CKD) is a progressive condition characterized by the gradual decline of kidney function, impairing the kidneys’ ability to effectively filter waste and excess fluids from the blood. This can lead to toxin buildup and complications in various bodily systems. The growing incidence of CKD is largely attributed to rising risk factors such as diabetes, hypertension, and obesity. Albumin and creatinine tests play a crucial role in diagnosing and monitoring CKD by measuring protein levels, particularly albumin, in urine and assessing kidney function through creatinine levels. These tests enable early detection and management of kidney damage. For example, in June 2023, Kidney Research UK, a UK-based non-profit organization, reported that approximately 7.2 million people in the UK, over 10% of the population are living with chronic kidney disease, including 3.25 million in advanced stages and 3.9 million in early stages. This number is projected to increase to 7.61 million by 2033. Consequently, the rising incidence of chronic kidney disease is fueling the growth of the albumin and creatinine tests market.

Leading companies in the market are focusing on innovative technologies, such as smartphone-based testing, to enhance kidney disease detection by analyzing urine samples and determining a patient’s albumin-to-creatinine ratio. Smartphone-based testing utilizes mobile technology, including apps and external devices, to conduct diagnostic tests and analyze health data, providing quick and convenient results. For instance, in July 2022, Healthy.io, a UK-based health technology company, received approval from the U.S. Food and Drug Administration (FDA) for its Minuteful Kidney Test, an AI-powered smartphone diagnostic tool. This non-invasive, user-friendly test allows patients to perform the test at home using just a smartphone and a specialized test strip, delivering real-time results. By enabling early detection of kidney disease, it empowers patients to monitor their health and seek timely medical intervention, potentially reducing the need for frequent doctor visits.

In September 2022, Sartorius AG, a Germany-based biotech research company, acquired Albumedix for $502 million. This acquisition aims to strengthen Sartorius’s production capabilities by expanding its portfolio with recombinant albumin, which is used in various biomanufacturing applications, including as an animal-free supplement to cell culture media and as a stabilizer for vaccines and viral treatments. Albumedix Ltd., a UK-based company, specializes in the development and commercialization of advanced therapies.

Major players in the albumin and creatinine tests market are Siemens Healthineers Company, Roche Diagnostics GmbH, Thermo Fisher Scientific Inc., Abbott Laboratories, FUJIFILM Corporation, Laboratory Corporation of America Holdings, Sysmex Corporation, Ortho Clinical Diagnostics Inc., Randox Laboratories Ltd., Nova Biomedical Corporation, Eagle Biosciences Inc., Sekisui Diagnostics LLC, BTNX Inc., RayBiotech Life Inc., ARKRAY Inc., PromoCell GmbH, Arbor Assays Inc., Teco Diagnostics Inc., J. Mitra & Co. Pvt. Ltd., Anamol Laboratories Pvt. Ltd.

North America was the largest region in the albumin and creatinine tests market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in albumin and creatinine tests report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the albumin and creatinine tests market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Albumin and creatinine tests measure the concentrations of these two substances in urine samples to provide a more accurate assessment of kidney health. By calculating the albumin-to-creatinine ratio, the test accounts for fluctuations in creatinine levels caused by factors such as hydration status.

The main product types for these tests include dipsticks and kits, analyzers, cartridges, reagents, and others. Dipsticks and kits play a crucial role in detecting albuminuria, a key indicator of chronic kidney disease. The different test types include blood and urine creatinine, urine albumin, and glycated albumin. These tests are utilized by various end users, including hospitals and clinics, diagnostic laboratories, research laboratories and institutes, and other healthcare facilities.

The albumin and creatinine tests market research report is one of a series of new reports that provides albumin and creatinine tests market statistics, including albumin and creatinine tests industry global market size, regional shares, competitors with an albumin and creatinine tests market share, detailed albumin and creatinine tests market segments, market trends and opportunities, and any further data you may need to thrive in the albumin and creatinine tests industry. This albumin and creatinine tests market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The albumin and creatinine tests market consists of revenues earned by entities by providing services such as diagnostic testing services, home testing kits, automated test solutions, and data analysis and reporting. The market value includes the value of related goods sold by the service provider or included within the service offering. The albumin and creatinine tests market also includes sales of reagents and consumables, testing instruments, home test kits, and software solutions. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.